Propylhexedrine

Summary

Propylhexedrine (CHEMBL2105275) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 155.28 Da · C10H21N

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105275
Name	Propylhexedrine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	7558
Molecular formula	C10H21N
Molecular weight	155.28
InChIKey	JCRIVQIOJSSCQD-UHFFFAOYSA-N

SMILES: CC(CC1CCCCC1)NC

IUPAC name: 1-cyclohexyl-N-methylpropan-2-amine

Also known as: Benzedrex, Dl-propylhexedrine, Dristan inhaler, Hydromethamphetamine, NSC-32410, Propilhexedrina, Propylhexedrine, Propylhexedrine dl-form, SID144206628, PROPYLHEXEDRINE, propylhexedrine

Patent coverage: 1,936 distinct patent families (7,850 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 7,849 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).